RedHawk Holdings Corp. (SNDD) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
RedHawk Holdings Corp. (SNDD) trades at $0.00001. RedHawk Holdings Corp. operates in the healthcare sector, focusing on medical device distribution and branded generic pharmaceuticals. The company serves various healthcare facilities and engages in property investment and financial services. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for SNDD: SNDD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SNDD against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on SNDD.
How is this calculated? →RedHawk Holdings Corp. (SNDD) Healthcare & Pipeline Overview
RedHawk Holdings Corp. operates within the healthcare sector, distributing medical devices and branded generic pharmaceuticals. Its diverse product range includes Sharps and Needle Destruction Devices, thermometers, and full-body X-ray scanners, catering to a broad customer base from hospitals to correctional facilities, alongside involvement in property investment and financial services.
What Is the Investment Thesis for SNDD?
RedHawk Holdings Corp. presents a speculative investment opportunity given its diverse business segments and focus on the healthcare sector. The company's involvement in medical devices, pharmaceuticals, and security systems offers potential revenue streams, but its negative profit margin of -200.8% raises concerns about profitability. A key value driver would be the successful commercialization and market penetration of its medical devices, such as the Sharps and Needle Destruction Devices and the Centri Controlled Entry System. Growth catalysts include expanding its distribution network and securing contracts with healthcare providers and government facilities. However, potential risks include the company's OTC market listing, which implies higher volatility and lower liquidity, and the need to achieve profitability amid intense competition. The company's ability to manage costs and effectively market its products will be critical for long-term success.
Based on FMP financials and quantitative analysis
SNDD Key Highlights
Market Cap of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -0.00 reflects current unprofitability, requiring careful evaluation of future earnings potential.
- Gross Margin of 54.6% suggests a strong ability to control production costs, but this needs to translate into overall profitability.
- Beta of 0.51 indicates lower volatility compared to the market, potentially offering some stability in a turbulent sector.
- The company operates in three segments: Land & Hospitality, Medical Device and Pharmaceutical, and Other Services, providing diversification but also complexity.
Who Are SNDD's Competitors?
SNDD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.3M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SNDD's Key Strengths?
Diverse product portfolio including medical devices, pharmaceuticals, and security systems.
- Established distribution network in the United States and the United Kingdom.
- Proprietary medical device technology.
- Involvement in multiple business segments.
What Are SNDD's Weaknesses?
Negative profit margin indicating financial instability.
- OTC market listing implying higher risk and lower liquidity.
- Limited brand recognition compared to larger competitors.
- Dependence on distribution agreements for certain products.
What Could Drive SNDD Stock Higher?
Potential new distribution agreements for medical devices and pharmaceuticals.
- Possible expansion into new geographic markets.
- Continued sales growth of branded generic pharmaceuticals.
- Development and commercialization of new medical devices.
- Strategic partnerships and acquisitions.
What Are the Key Risks for SNDD?
Financial-distress signal — its Altman Z-Score of -7.54 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition from larger medical device and pharmaceutical companies.
- Regulatory changes affecting the healthcare and security industries.
- Economic downturn impacting healthcare spending.
- Negative profit margin indicating financial instability.
- OTC market listing implying higher risk and lower liquidity.
What Are the Growth Opportunities for SNDD?
- Expansion of Medical Device Sales: The market for Sharps and Needle Destruction Devices is growing due to increasing awareness of healthcare worker safety and the need for proper disposal of medical waste. RedHawk can capitalize on this by expanding its sales and distribution network to target hospitals, clinics, and other healthcare facilities. The global sharps disposal containers market is projected to reach $1.5 billion by 2027, offering a substantial growth opportunity.
- Increased Distribution of Branded Generic Pharmaceuticals: The demand for affordable generic drugs is rising, particularly in the United States and the United Kingdom. RedHawk can leverage its existing distribution channels to increase the sales of its branded generic pharmaceuticals, such as Paracetamol, Glipizide, and Omeprazole. The global generic drugs market is expected to reach $459 billion by 2028, presenting a significant growth avenue.
- Penetration of the Security Systems Market: With increasing security concerns, the market for full-body X-ray scanners and entry systems is expanding. RedHawk's Centri Controlled Entry System offers a potential solution for correctional facilities, schools, and other high-security environments.
- Leveraging Telehealth and Remote Monitoring Solutions: The COVID-19 pandemic has accelerated the adoption of telehealth and remote patient monitoring technologies. RedHawk can integrate its medical devices, such as the carotid artery digital non-contact thermometers, with telehealth platforms to offer remote patient monitoring solutions. The global telehealth market is expected to reach $55.6 billion by 2027, creating a potential growth area.
- Strategic Partnerships and Acquisitions: RedHawk can pursue strategic partnerships and acquisitions to expand its product portfolio, distribution network, and market reach. Collaborating with other medical device manufacturers or pharmaceutical companies can provide access to new technologies and markets. Identifying synergistic acquisition targets can accelerate growth and enhance the company's competitive position. The timeline for these opportunities depends on market conditions and available capital.
What Are SNDD's Competitive Advantages?
- Proprietary medical device technology, such as Sharps and Needle Destruction Devices.
- Established distribution network for medical devices and pharmaceuticals.
- Diversified business segments providing multiple revenue streams.
- Strategic partnerships with manufacturers and distributors.
What Does SNDD Do?
RedHawk Holdings Corp., established in 2005 and headquartered in Lafayette, Louisiana, has evolved from Independence Energy Corp. to a diversified entity primarily focused on the healthcare sector. The company operates through three segments: Land & Hospitality, Medical Device and Pharmaceutical, and Other Services. Its core business involves the sale and distribution of medical devices and branded generic pharmaceutical drugs in the United States and the United Kingdom. RedHawk manufactures and sells specialized medical devices such as Sharps and Needle Destruction Devices, carotid artery digital non-contact thermometers, and the Centri Controlled Entry System, a full-body X-ray scanner. Additionally, the company distributes WoundClot, a bleeding control medical device, Berrcom JXB178 infrared non-contact thermometers, and Zonis. The company also offers a range of personal protective equipment, including face masks, face shields, and ultraviolet sanitation lights. Beyond healthcare, RedHawk is involved in commercial and residential property investment and leasing, the sale of point-of-entry full-body security systems, and specialized financial services. The company serves a diverse clientele, including retail pharmacies, hospitals, physicians' offices, private and public healthcare clinics, corrections facilities, schools, veterinary clinics, emergency services, first responders, municipalities, and long-term care facilities.
What Products and Services Does SNDD Offer?
- Manufactures and sells Sharps and Needle Destruction Devices.
- Distributes carotid artery digital non-contact thermometers.
- Sells Centri Controlled Entry System, a full body X-ray scanner.
- Distributes WoundClot, a bleeding control medical device.
- Sells Berrcom JXB178 infrared non-contact thermometers.
- Offers a line of face masks and face shields.
- Sells ultraviolet sanitation lights.
- Distributes branded generic pharmaceuticals.
How Does SNDD Make Money?
- Direct sales of manufactured medical devices to healthcare facilities and other institutions.
- Distribution of medical devices and pharmaceuticals through partnerships and agreements.
- Revenue generation from property investment and leasing activities.
- Provision of specialized financial services.
What Industry Does SNDD Operate In?
RedHawk Holdings Corp. operates in the medical device and pharmaceutical industry, a sector characterized by innovation, regulation, and intense competition. The pharmaceutical market is similarly large and growing, fueled by increasing healthcare expenditure and the development of new therapies. RedHawk competes with larger, more established companies like APTCF (Applied Concepts), CKNTF (Canna-Global Acquisition Corp), EDNEF (Edene), MMNFF (MedMen Enterprises), and MRVT (Murrieta Genomics), requiring a focus on niche markets and differentiated products to gain market share.
Who Are SNDD's Key Customers?
- Retail pharmacies
- Hospitals and physicians' offices
- Private and public healthcare clinics
- Corrections facilities and schools
- Veterinary clinics and emergency services
Key Financial Metrics
Return on equity for RedHawk Holdings Corp. stands at 175.4%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.29 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
RedHawk Holdings Corp. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Lafayette, US. The company is led by CEO Philip C. Spizale. SNDD has traded publicly since 2012.
Financial Health
RedHawk Holdings Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -7.54 places it in the distress zone, a signal of elevated financial risk.
Insider Activity
The most recent 11 insider filings for RedHawk Holdings Corp. break down as 7 sales and 4 purchases. On net that is roughly 247.4M shares acquired (about $133.9B) — insiders putting money in tends to read as conviction.
SNDD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in RedHawk's future, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively, with increased discussions around the company's strategic initiatives and growth prospects.
- Recent announcements about new partnerships have generated excitement among investors, positioning RedHawk for potential expansion.
- The overall market sentiment towards small-cap stocks has been improving, creating a favorable environment for companies like RedHawk.
Bear Case
- There are concerns about the company's financial health, with ongoing discussions in the community about its ability to sustain operations without additional funding.
- Recent volatility in the stock has led to skepticism among traders, with some questioning the long-term viability of RedHawk's business model.
- Negative sentiment from analysts regarding the competitive landscape may be weighing on investor confidence, as challenges in the sector remain significant.
- The lack of clear, positive catalysts in the near term could lead to hesitation among potential investors, impacting demand.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SNDD Latest News
No recent news available for SNDD.
SNDD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SNDD.
Price Targets
Wall Street price target analysis for SNDD.
SNDD MoonshotScore
What does this score mean?
The MoonshotScore rates SNDD 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Philip C. Spizale
CEO
Philip C. Spizale serves as the Chief Executive Officer of RedHawk Holdings Corp. His background includes experience in finance and management, with a focus on strategic planning and business development. He has been involved in various leadership roles within the company, guiding its transition from Independence Energy Corp. to RedHawk Holdings Corp. Spizale's expertise lies in identifying growth opportunities and implementing strategies to enhance shareholder value. His leadership is crucial for navigating the company's diverse business segments and competitive landscape.
Track Record: Under Philip C. Spizale's leadership, RedHawk Holdings Corp. has diversified its business operations to include medical devices, pharmaceuticals, and security systems. Key achievements include the development and commercialization of proprietary medical devices, such as the Sharps and Needle Destruction Devices, and the establishment of distribution agreements for branded generic pharmaceuticals. However, the company's financial performance, particularly its profitability, remains a challenge.
SNDD OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that RedHawk Holdings Corp. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries higher risks compared to stocks listed on major exchanges like NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Limited financial disclosure due to OTC Other tier requirements.
- Lower trading volume and liquidity compared to major exchanges.
- Higher price volatility and potential for manipulation.
- Increased risk of fraud and scams.
- Lack of regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Check for any legal or regulatory issues.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- The company has been in operation since 2005.
- RedHawk Holdings Corp. has a diverse product portfolio.
- The company has established distribution agreements.
- RedHawk Holdings Corp. has a CEO in place.
RedHawk Holdings Corp. Healthcare Stock: Key Questions Answered
What does RedHawk Holdings Corp. do?
RedHawk Holdings Corp. operates as a diversified holding company with a primary focus on the healthcare sector. The company manufactures, sells, and distributes medical devices, including Sharps and Needle Destruction Devices and carotid artery digital non-contact thermometers. Additionally, RedHawk distributes branded generic pharmaceutical drugs, such as Paracetamol, Glipizide, and Omeprazole.
What do analysts say about SNDD stock?
As of March 18, 2026, formal analyst ratings for RedHawk Holdings Corp. (SNDD) are unavailable, likely due to its OTC listing and small market capitalization. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors. Key valuation metrics, such as the negative P/E ratio, indicate current unprofitability.
What are the main risks for SNDD?
Investing in RedHawk Holdings Corp. (SNDD) involves several risks. The company's OTC market listing implies higher volatility and lower liquidity compared to stocks listed on major exchanges. The negative profit margin indicates financial instability and the need for improved profitability. Intense competition from larger medical device and pharmaceutical companies poses a threat to market share.
What are the key factors to evaluate for SNDD?
Evaluate SNDD on fundamentals, analyst consensus, and risk factors. RedHawk Holdings Corp. presents a speculative investment opportunity given its diverse business segments and focus on the healthcare sector. Not financial advice.
How frequently does SNDD data refresh on this page?
SNDD's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SNDD's recent stock price performance?
RedHawk Holdings Corp. (SNDD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio including medical devices, pharmaceuticals, and security systems. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SNDD overvalued or undervalued right now?
RedHawk Holdings Corp. (SNDD) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SNDD before investing?
Before investing in RedHawk Holdings Corp. (SNDD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage and financial data availability for OTC stocks.
- AI analysis pending for SNDD, which may provide further insights.